

Applied and Environmental
Microbiology

Phylogenetically Related Argentinean and Australian Escherichia coli O157 Isolates Are Distinguished by Virulence Clades and Alternative Shiga Toxin 1 and 2 Prophages

Glen E. Mellor, Eby M. Sim, Robert S. Barlow, Beatriz A. D'Astek, Lucia Galli, Isabel Chinen, Marta Rivas and Kari S. Gobius

Appl. Environ. Microbiol. 2012, 78(13):4724. DOI: 10.1128/AEM.00365-12.

Published Ahead of Print 27 April 2012.

Updated information and services can be found at:
<http://aem.asm.org/content/78/13/4724>

These include:

REFERENCES

This article cites 44 articles, 25 of which can be accessed free at: <http://aem.asm.org/content/78/13/4724#ref-list-1>

CONTENT ALERTS

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), [more»](#)

Information about commercial reprint orders: <http://journals.asm.org/site/misc/reprints.xhtml>
To subscribe to to another ASM Journal go to: <http://journals.asm.org/site/subscriptions/>

Journals.ASM.org

Phylogenetically Related Argentinean and Australian *Escherichia coli* O157 Isolates Are Distinguished by Virulence Clades and Alternative Shiga Toxin 1 and 2 Prophages

Glen E. Mellor,^a Eby M. Sim,^a Robert S. Barlow,^a Beatriz A. D'Astek,^b Lucia Galli,^b Isabel Chinen,^b Marta Rivas,^b and Kari S. Gobius^a

CSIRO Food and Nutritional Sciences, Archerfield BC, QLD, Australia,^a and Servicio Fisiopatogenia, Instituto Nacional de Enfermedades Infecciosas—ANLIS “Dr. Carlos G. Malbrán,” Ciudad Autónoma de Buenos Aires, Argentina^b

Shiga toxigenic *Escherichia coli* O157 is the leading cause of hemolytic uremic syndrome (HUS) worldwide. The frequencies of *stx* genotypes and the incidences of O157-related illness and HUS vary significantly between Argentina and Australia. Locus-specific polymorphism analysis revealed that lineage I/II (LI/II) *E. coli* O157 isolates were most prevalent in Argentina (90%) and Australia (88%). Argentinean LI/II isolates were shown to belong to clades 4 (28%) and 8 (72%), while Australian LI/II isolates were identified as clades 6 (15%), 7 (83%), and 8 (2%). Clade 8 was significantly associated with Shiga toxin bacteriophage insertion (SBI) type *stx*₂ (locus of insertion, *argW*) in Argentinean isolates ($P < 0.0001$). In Argentinean LI/II strains, *stx*₂ is carried by a prophage inserted at *argW*, whereas in Australian LI/II strains the *argW* locus is occupied by the novel *stx*₁ prophage. In both Argentinean and Australian LI/II strains, *stx*_{2c} is almost exclusively carried by a prophage inserted at *sbcb*. However, alternative *q*₉₃₃- or *q*₂₁-related alleles were identified in the Australian *stx*_{2c} prophage. Argentinean LI/II isolates were also distinguished from Australian isolates by the presence of the putative virulence determinant ECSP_3286 and the predominance of motile O157:H7 strains. Characteristics common to both Argentinean and Australian LI/II O157 strains included the presence of putative virulence determinants (ECSP_3620, ECSP_0242, ECSP_2687, ECSP_2870, and ECSP_2872) and the predominance of the *tir*255T allele. These data support further understanding of O157 phylogeny and may foster greater insight into the differential virulence of O157 lineages.

Escherichia coli O157 is a food-borne pathogen of global significance. Human infection can result in progressive sequelae extending from bloody diarrhea to hemolytic uremic syndrome (HUS), giving rise to the designation of this pathogen as enterohemorrhagic *E. coli* (EHEC) (5, 33). The predominant source of O157 is cattle (12) and undercooked beef products (2); however, secondary sources, including leafy green vegetables, apple cider, and dairy products which have been contaminated with manure, are also vehicles for food-borne infection (6).

Molecular typing and microbial genomics have facilitated the characterization and comparison of O157 strains isolated from human and animal sources. These studies have been directed to the identification of O157 factors influencing successful human infection. Such analyses have included characterization of Shiga toxin genotypes (32), locus-specific polymorphism assays (LSPA) (40, 44), clade typing (24, 34), allelic variation of virulence genes (4), and Shiga toxin bacteriophage insertion (SBI) site analysis (3, 36, 38).

For some time, it has been known that O157 strains carrying *stx*₂ predominate in human infection, causing more severe disease symptoms than *stx*_{2c} strains (10, 28). Evidence for a hypervirulent clade of O157 was first demonstrated by Manning et al. (24) in their analysis of O157 outbreak isolates associated with raw spinach consumption in the United States in 2006. This evidence was further supported by genotype comparisons demonstrating that hypervirulent clade 8 isolates can also be designated LSPA-6 lineage I/II (LI/II) with unique SBI genotypes (19). LI/II clade 8 strains are characterized by insertion of the *stx*₂ prophage in *argW* (18), frequently also possess the *stx*_{2c} prophage inserted in *sbcb*, and do not possess *stx*₁ prophage (24).

While the studies described above have been informative, they

have focused largely on isolates from geographic regions in the Northern Hemisphere. In those studies, which assessed the genotypes of isolates from diverse geographic regions, some limited indications of strain divergence have been observed. For example, O157:H⁻ strains carrying *stx*_{2c} (either alone or in association with *stx*₁) dominate from both clinical and cattle sources in Australia (8). Human O157 isolates in Australia also possess SBI genotypes that are different from O157 isolates of human origin in the United States (39), suggesting the possibility of different *stx* prophage configurations in human isolates in these separate countries. More recent striking data indicate that O157 strains with the *stx*₂ *stx*_{2c} genotype are predominant in both Argentinean cattle (56%) and clinical cases, where such strains are implicated in >90% of postenteric HUS (22). However, O157 strains with the *stx*₂ *stx*_{2c} genotype are very rare in Australia (8). Notable differences in Argentinean and Australian O157 epidemiologies are also reflected in the incidence of human cases. A total of 0.24 cases per 100,000 population in Australia (27) and 13.9 cases per 100,000 children younger than 5 years in Argentina (35) are caused mainly by *E. coli* O157.

To further examine the relatedness of Southern Hemisphere *E. coli* O157 isolates, we have now compared human and bovine O157 isolates from Argentina and Australia. Strain motility, *stx*

Received 7 February 2012 Accepted 13 April 2012

Published ahead of print 27 April 2012

Address correspondence to Kari S. Gobius, kari.gobius@csiro.au.

Copyright © 2012, American Society for Microbiology. All Rights Reserved.

doi:10.1128/AEM.00365-12

TABLE 1 Bacteriophage insertion site primers

Target	Primer	Sequence	Cycle conditions
<i>argW</i> left junction	int4045F	5'-ACCATCGAGTAGGCGGTATG-3'	96°C for 10 s, 60°C for 30 s, 72°C for 40 s
	int1810R	5'-ATTTCAGCAGGGCCAGAGTA-3'	
<i>argW</i> right junction	yfdCF	5'-ACTGGAGCGATTTCATCTGG-3'	96°C for 10 s, 60°C for 30 s, 72°C for 40 s
	phi1810stx2F	5'-GGTTGAGCGGGATATGAAAA-3'	
<i>sbcB</i> left junction	sbcBF	5'-ATTGTCGCGCTAAAGCTGAT-3'	96°C for 10 s, 60°C for 30 s, 72°C for 45 s
	stx2cphiB	5'-CAACGATGCTCGTTATGGTG-3'	
<i>sbcB</i> right junction	stx2cphiA	5'-GGACAACAGCGCACAGTAAA-3'	96°C for 10 s, 60°C for 30 s, 72°C for 45 s
	sbcBR1	5'-CGGGCTTGACAGTAAAAGACT-3'	
<i>prfC</i>	prfCF	5'-CGATGCCGCTTACTCAAGA-3'	96°C for 10 s, 60°C for 30 s, 72°C for 45 s
	prfCR	5'-GAACAGCAGCACCTTCTCG-3'	
<i>yecE</i>	yecEF	5'-ATTGCCGAAGATGCCTGTAG-3'	96°C for 10 s, 60°C for 30 s, 72°C for 45 s
	yecER	5'-CATACAGCGCGCTTACCATA-3'	

genotyping, *q* allele genotyping, LSPA-6 genotyping, single nucleotide polymorphism (SNP) clade typing, *stx* prophage analysis, and putative virulence factor genotyping have been applied to characterize properties of O157 isolates from both countries.

MATERIALS AND METHODS

Bacterial strains. *E. coli* O157 strains from Argentina (human, $n = 30$; cattle, $n = 30$) and Australia (human, $n = 30$; cattle, $n = 30$) comprising isolates that vary in source, pulsed-field gel electrophoresis (PFGE) type, *stx* genotype, and geographical and temporal isolation were included in this study. Bacterial strains were recovered from -80°C protect preservers (Oxoid, Basingstoke, United Kingdom) in Luria-Bertani (LB) broth at 37°C overnight and stored on tryptone soya agar (TSA; Oxoid) for the duration of the study. Serotype O157 and motility were determined as described by Fegan and Desmarchelier (8). *Escherichia coli* K-12 Q358 Sm^r (15) lysogens were created from Argentinean and Australian isolates carrying *stx*₁, *stx*₂, and *stx*_{2c}-encoding prophages. *E. coli* O157 strains Sakai, EDL933, EC623 (16), EC1812 (16); K-12 strains MG1655 and Q358 Sm^r; and *Salmonella* Braenderup H9812 (ATCC BAA-664) were used as controls when appropriate.

Analysis of *stx* genes. Isolates were investigated for the presence of *stx*₁ and *stx*₂ using previously published multiplex primers and PCR conditions (30). Restriction fragment length polymorphism was performed on isolates that tested positive for *stx*₂ to discriminate between *stx*₂ and *stx*_{2c} as previously described (24). Isolates that tested positive for the presence of *stx*₂ and/or *stx*_{2c} were subsequently tested for *stx*₂-specific *q*₉₃₃ and *stx*_{2c}-specific *q*₂₁ alleles using primer pairs Q-stx2-F (5'-AAAGCGGAGG GGATTGTTGAAGGC-3')/stx2_rev (5'-CCGGGAATAGGATACCGAA G-3') and Qc-stx2-F (5'-GAACAGCATGAGTGGCTGAA-3')/stx2_rev, respectively, with the following cycling conditions; 96°C for 10 s; 60°C for 30 s; 72°C for 45 s. A representative set of *stx*₂ (987-bp) and *stx*_{2c} (1,177-bp) amplicons were gel purified and used as templates in capillary sequence reactions (Australian Genome Research Facility, St. Lucia, Australia) to confirm the sequence of *q*₉₃₃ and *q*₂₁ regions upstream of the *stx*₂ and *stx*_{2c} genes, respectively.

Determination of Shiga toxin bacteriophage insertion (SBI) loci and *stx* lysogen formation. Primer sets targeting SBI site boundary sequences were used to determine the *stx* prophage occupancy of *E. coli* O157 loci *yehV* (*mhrA*) and *wrbA* using the method of Shaikh and Tarr (36). Additional primers were designed to determine the occupancy of *argW*, *sbcB*, *prfC*, and *yecE* (Table 1). The SBI sites of *E. coli* K-12 *stx* lysogens were determined in the same manner. Mitomycin C ($0.5\ \mu\text{g ml}^{-1}$) was used to induce *stx* prophage from wild-type O157 strains (1). *E. coli* K-12 *stx*

lysogen candidates were selected as survivors following *stx* phage infection (1). Survivors were selected as colonies growing within zones of *stx* phage lysis in semisolid layered agar plates or as colonies streaked from *stx* phage infection broth cultures. *stx* lysogen candidates were confirmed using primer pairs specific for *stx*₁, *stx*₂, or *stx*_{2c} as appropriate (24, 30); the absence of O157 *eae* and *hxA* genes in lysogens was also confirmed by PCR (30).

LSPA-6 typing. Isolates were further characterized using the LSPA-6 method as previously described (40). Briefly, fluorescent-labeled amplicons were diluted 1/20 and separated by capillary electrophoresis using an Applied Biosystems 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA), DS-33 matrix, and GeneScan600 LIZ size standard. Amplicon size was determined using PeakScanner software (version 1.0; Applied Biosystems). Three isolates (EC623, EC1812, and MG1655) with known LSPA-6 patterns were included in each run as positive controls.

O157 clade and *tir255T/A* allele genotyping. O157 virulence clades were identified by targeted SNP typing using SYBR green-based real-time PCR with hairpin primers. Clades 1 to 3 and 8 were identified using the SNPs described by Riordan et al. (34). The remaining O157 clades (4 to 7 and 9) were identified using SNPs or combinations of SNPs previously shown to be specific for individual clades (24). Polymorphisms of *tir* were detected using a probe-based real-time PCR method (38).

PCR genotyping of O157 virulence factors. The gene encoding the H7 flagellum antigen, *fliC*_{H7}, was detected using the method of Gannon et al. (11). Isolates were screened for the locus tags corresponding to putative virulence determinants ECSP_0242, ECSP_1773, ECSP_2687, ECSP_2870, ECSP_2872, ECSP_3286, and ECSP_3620 as previously described (18).

Statistical analysis. Statistical analyses were performed using a 2-by-2 contingency table and Fisher's exact test (Minitab15; Minitab Inc., Minneapolis, MN). *P* values were two-tailed, and groups were considered significantly different if *P* values were <0.05 . When multiple comparisons were performed, Bonferroni *P* value correction was incorporated.

Nucleotide sequence accession numbers. The sequences reported in this paper have been deposited in the GenBank database (accession numbers HQ993494 to HQ993501).

RESULTS

Motility. All Argentinean strains (60/60) were *E. coli* O157:H7 (motile), while 14/60 Australian strains were *E. coli* O157:H7 and the remainder were *E. coli* O157:H⁻ (nonmotile). Argentinean O157 strains were significantly more often motile than Australian O157 strains ($P = 0.0001$).

TABLE 2 Distribution of *stx* genotypes in Argentinean and Australian *E. coli* O157

<i>stx</i> genotype ^a	No. of isolates					
	Argentina			Australia		
	Human (n = 30)	Cattle (n = 30)	Total (n = 60)	Human (n = 30)	Cattle (n = 30)	Total (n = 60)
<i>stx</i> ₁	1	2	3	3		3
<i>stx</i> ₁ <i>stx</i> ₂		2	2	1	1	2
<i>stx</i> ₁ <i>stx</i> ₂ <i>stx</i> _{2c}	3	3	6			
<i>stx</i> ₁ <i>stx</i> _{2c}	2	4	6	17	20	37
<i>stx</i> ₂	6	3	9			
<i>stx</i> ₂ <i>stx</i> _{2c}	16	10	26		1	1
<i>stx</i> _{2c}	2	6	8	9	8	17

^a *stx* genotype refers to the Shiga toxin genotype.

***stx* genotyping.** Argentinean and Australian O157 isolates in this study comprised seven and five different *stx* genotypes, respectively (Table 2). Among Argentinean isolates, *stx*₂ *stx*_{2c} represented the largest group (26/60) followed by *stx*₂ alone (9/60) and *stx*_{2c} alone (8/60). The predominant *stx* genotypes of Australian isolates were identified as *stx*₁ *stx*_{2c} (37/60) and *stx*_{2c} alone (17/60). A significant difference was observed between the predominant genotypes from Argentina (*stx*₂ *stx*_{2c}) and Australia (*stx*₁ *stx*_{2c}) ($P < 0.0001$).

LSPA-6 typing. LSPA-6 lineage I/II dominated in isolates from both Argentina (90%) and Australia (88%) (Fig. 1). There was no significant difference in the prevalence of LI/II isolates from both countries. LI isolates were present in both countries, accounting for 4% of the 120 isolates tested. All *stx*₂-positive LI isolates from both Argentina and Australia carried the *stx*₂ (*wrbA*) prophage. In contrast, LII isolates were present only in Australia, with 7% (4/60) of isolates shown to possess this genotype. No lineage designation could

be assigned to three Argentinean and one Australian isolate due to the absence of Z5935 allele amplicons from these isolates.

Virulence clade determination. Argentinean LI/II isolates ($n = 54$) were shown to belong to clades 4 (28%) and 8 (72%). Australian LI/II isolates ($n = 53$) were identified as clades 6 (15%), 7 (83%), and 8 (2%). No clade 4 isolates were characterized among Australian O157 and, conversely, no clade 6 or 7 isolates were observed among Argentinean O157. Clinical isolates from Argentina and Australia were predominately clade 8 (80%) and clade 7 (90%), respectively (Fig. 2). However, among cattle isolates, clade 4 (43%) and clade 8 (50%) were prevalent in Argentina, while clade 6 (23%) and clade 7 (70%) predominated in Australia. In Argentina, clade 8 isolates dominated in both cattle (50%) and humans (80%) but were present in significantly more human isolates than cattle isolates ($P = 0.0292$). A similar pattern of clade dominance was observed for Australian isolates, where clade 7 dominated in both cattle (70%) and humans (90%). However, the different distribution of clade 7 in human and cattle isolates was not statistically significant.

Shiga toxin bacteriophage insertion site characterization. The insertion of Shiga toxin prophage in previously described O157 chromosomal loci *yehV*, *wrbA*, *sbcB*, *argW*, *yecE*, and *prfC* was investigated (Table 3). In Argentinean O157, *stx*₂- and *stx*_{2c}-associated prophages were inserted in the *argW* (37/43 isolates) and *sbcB* (46/46 isolates) loci, respectively. The *stx*₂ prophage of four Argentinean O157 strains was not inserted in any of the loci studied. Australian O157 strains also showed association of *stx*_{2c} with prophage insertion in the *sbcB* locus (54/55 isolates). In a single *stx*_{2c}-positive Australian strain, the presumptive *stx*_{2c} prophage was not inserted in any of the loci studied. A separate single Australian isolate showed *stx*₂-associated prophage insertion in the *argW* locus. In *stx*₁-positive LI/II Argentinean strains ($n = 14$),




FIG 1 Distribution of LSPA-6 genotypes among *E. coli* O157 isolates from Argentina and Australia. No lineage designation could be assigned to three Argentinean isolates and one Australian isolate due to the absence of the Z5935 allele amplicons. These isolates have been referred to as untypable.




FIG 2 Distribution of *E. coli* O157 virulence clades in isolates from Argentina and Australia. Isolates are grouped according to country and source, and the distribution of clades within each group is displayed as a percentage of total isolates within the group.

the *stx*₁ prophage was not inserted in any of the loci examined. However, in these strains (and in all other Argentinean LI/II and lineage untypeable strains [*n* = 43]), the *yehV* locus showed evidence that it was occupied by a non-*stx* prophage. LI Argentinean (*n* = 2) and Australian (*n* = 2) *E. coli* O157 isolates carrying *stx*₁

*stx*₂ showed association with prophage insertion in the *yehV* and *wrbA* loci, respectively. In contrast, all other Australian O157 strains carrying *stx*₁ (*n* = 40) showed *stx*₁ association with prophage insertion in the *argW* locus, suggesting the presence of a novel O157 *stx*₁ bacteriophage in these strains.

TABLE 3 Characterization of *E. coli* O157 isolates by O157 clade type and *stx* bacteriophage insertion site

Country	Clade	No. of isolates	SBI ^a		
			<i>stx</i> ₁	<i>stx</i> ₂	<i>stx</i> _{2c}
Argentina	3	1	<i>yehV</i>		
		2	<i>yehV</i>	<i>wrbA</i>	
	4	2	Unk		
		3		Unk	
		6	Unk		<i>sbcB</i>
	5			<i>sbcB</i>	
	1		Unk	<i>sbcB</i>	
	1		<i>argW</i>	<i>sbcB</i>	
	8	3		<i>sbcB</i>	<i>sbcB</i>
		6	Unk	<i>argW</i>	<i>sbcB</i>
6			<i>argW</i>		
24			<i>argW</i>	<i>sbcB</i>	
Australia	2	1	<i>yehV</i>	<i>wrbA</i>	
		1	<i>yehV</i>	<i>wrbA</i>	
	6	1			<i>sbcB</i>
		8	<i>argW</i>		<i>sbcB</i>
	7	3	<i>argW</i>		
		1	<i>argW</i>		Unk
		28	<i>argW</i>		<i>sbcB</i>
	8	16		<i>sbcB</i>	<i>sbcB</i>
		1		<i>argW</i>	<i>sbcB</i>

^a SBI, Shiga toxin bacteriophage insertion locus; Unk, unknown. The SBI for some *stx* prophages of O157 isolates remain unknown. In such cases, *stx* lysogens were not isolated and SBI mapping did not correlate with *stx* genotype data for any of the five Shiga toxin prophage loci examined.

The occurrence of SBI type *stx*₂ (*argW*)/*stx*_{2c} (*sbcB*) in Argentinean isolates was significantly different from the occurrence in Australian isolates (*P* < 0.0001) (Table 3). Similarly, the occurrence of SBI type *stx*₁ (*argW*)/*stx*_{2c} (*sbcB*) in Australian isolates was significantly different to the occurrence in Argentinean isolates (*P* < 0.0001). In addition, clade 8 was significantly associated with SBI type *stx*₂ (*argW*) in Argentinean isolates (*P* < 0.0001).

Induced *stx*₁, *stx*₂, and *stx*_{2c} phages insert at phage-specific loci to form *E. coli* K-12 lysogens. The *stx* prophage of Argentinean and Australian O157 strains was further investigated by prophage induction and lysogeny of an *E. coli* K-12 host strain in order to demonstrate unambiguous linkage of *stx* genotypes with particular phages (Table 4). Representative O157 strains were induced with mitomycin C followed by harvest of resultant phage lysates and infection of *E. coli* strain Q358 Sm^r. Putative *stx*₁, *stx*₂, and *stx*_{2c} lysogens were selected as Q358 Sm^r survivors following phage infection and demonstration of lysogen resistance to streptomycin. All lysogen strains were confirmed by *stx*-specific PCR to carry only the predicted *stx* genes introduced by the specific infecting *stx* phage. The absence of PCR amplification of O157 virulence genes *eae* and *ehxA* was confirmed for all *stx* lysogens. Despite repeated efforts, K-12 lysogens from Argentinean O157 *stx*₁ or *stx*_{2c} prophage were not obtained. SBI analysis then demonstrated that the *stx*₂ (*argW*) phage induced from Argentinean O157 strains inserted in the *argW* locus of *E. coli* Q358 Sm^r. SBI analysis also demonstrated that *stx*₂ (*wrbA*) phage induced from

TABLE 4 Genotypes of *E. coli* K12 Q358 Sm^f lysogen strains carrying Argentinean and Australian O157 *stx*₁, *stx*₂, or *stx*_{2c} prophages

O157 donor strain	Lysogen genotype ^a						Integration site	<i>q</i> allele
	<i>stx</i> ₁	<i>stx</i> ₂	<i>stx</i> _{2c}	<i>eae</i>	<i>ehxA</i>	Sm ^f		
I-004	–	+	–	–	–	+	<i>wrbA</i>	<i>q</i> ₉₃₃
I-003	–	+	–	–	–	+	<i>wrbA</i>	<i>q</i> ₉₃₃
313/99	–	+	–	–	–	+	<i>argW</i>	<i>q</i> ₉₃₃
129/01	–	+	–	–	–	+	<i>argW</i>	<i>q</i> ₉₃₃
210/03	–	+	–	–	–	+	<i>argW</i>	<i>q</i> ₉₃₃
326/03	–	+	–	–	–	+	<i>argW</i>	<i>q</i> ₉₃₃
755/05	–	+	–	–	–	+	<i>argW</i>	<i>q</i> ₉₃₃
112/07	–	+	–	–	–	+	<i>argW</i>	<i>q</i> ₉₃₃
145/98	–	+	–	–	–	+	<i>argW</i>	<i>q</i> ₉₃₃
FP-196	–	+	–	–	–	+	<i>argW</i>	<i>q</i> ₉₃₃
353/00	–	+	–	–	–	+	<i>argW</i>	<i>q</i> ₉₃₃
EC3185	+	–	–	–	–	+	<i>argW</i>	NA ^b
EC3206	+	–	–	–	–	+	<i>argW</i>	NA
EC2441	–	–	+	–	–	+	<i>sbcB</i>	<i>q</i> ₂₁
EC3197	–	–	+	–	–	+	<i>sbcB</i>	<i>q</i> ₂₁
EC3204	–	–	+	–	–	+	<i>sbcB</i>	<i>q</i> ₉₃₃

^a +, present; –, absent.^b NA, not applicable for *stx*₁ prophage.

Argentinean O157 strains inserted in the *wrbA* locus of *E. coli* Q358 Sm^f. Similarly, *stx*_{2c} phage induced from Australian O157 demonstrated insertion specificity for the *sbcB* gene in *E. coli* Q358 Sm^f lysogens. Lysogenic insertion of *stx*₁ phage from Australian O157 LI/II isolates, into the *E. coli* K-12 *argW* locus, was also demonstrated. Mitomycin C induction of all *stx*₁, *stx*₂, and *stx*_{2c} lysogens demonstrated that *de novo stx*₁, *stx*₂, and *stx*_{2c} phages, able to form infectious plaques on *E. coli* Q358 Sm^f indicator lawns, were produced from the newly created lysogens. Confirmation of *stx*₁ linkage to prophage specifically integrating at the *argW* SBI locus of their lysogen host demonstrated the novelty of the *stx*₁ (*argW*) phage from Australian O157 strains.

***q* gene allelic variation upstream of *stx*_{2c} in Argentinean and Australian O157.** The prevalences of *q*₉₃₃ and *q*₂₁ alleles in Australian and Argentinean O157 isolates were determined with *q* allele-specific PCR. Argentinean strains carrying *stx*₂ (*n* = 43) tested positive for *q*₉₃₃, while those carrying *stx*_{2c} (*n* = 46) tested positive for *q*₂₁. Unexpectedly, Australian strains carrying *stx*_{2c} (*n* = 55) showed evidence for *q*₉₃₃ and *q*₂₁ gene allelic variation upstream of *stx*_{2c}. Eighteen Australian O157 strains carrying *stx*_{2c} possessed *q*₉₃₃ (33%) and 36 possessed *q*₂₁ (65%). A single *stx*_{2c}-carrying Australian isolate showed evidence for deletion disruption of the *q-stx*_{2cA} region which prevented *q* allele designation in this isolate. To confirm the unusual presence of the *q*₉₃₃ allele upstream of *stx*_{2c} in 18 Australian isolates and verify that designated *q*₉₃₃ and *q*₂₁ amplicons matched the appropriate gene sequences, the DNA sequences of 7 representative *q* allele amplicons were compared. The sequences of *q*₉₃₃ and *q*₂₁ gene regions from representative Argentinean *stx*₂ and Australian *stx*_{2c} (including both *q*₉₃₃ and *q*₂₁ allelic forms) O157 strains showed greater than 99% identity to *stx*₂ *q*₉₃₃ and *stx*_{2c} *q*₂₁ nucleotide regions from strain TW14359, respectively. Additional confirmation of *stx*_{2c} *q*₉₃₃ and *stx*_{2c} *q*₂₁ gene allelic variation was shown in *stx*_{2c} lysogen strains. Representative *E. coli* K-12 lysogens transduced with Australian *stx*_{2c} prophage were shown to possess the *q*₂₁- or *q*₉₃₃-related allelic forms (Table 4). Using these approaches, the presence of novel *stx*_{2c} *q*₉₃₃ in some strains of Australian O157 was verified.

TABLE 5 *Escherichia coli* O157 isolates positive for putative virulence determinants

Determinant ^a	No. (%) of isolates	
	Argentina (<i>n</i> = 60)	Australia (<i>n</i> = 60)
<i>tir</i> 255T	60 (100)	56 (93)
ECSP_0242	56 (93)	55 (92)
ECSP_1773	16 (27)	14 (23)
ECSP_2687	46 (77)	54 (90)
ECSP_2870/2872	38 (63)	24 (40)
ECSP_3286	36 (60) ^b	1 (2) ^b
ECSP_3620	57 (95)	58 (97)

^a ECSP locus tags indicate putative virulence determinants identified in the *E. coli* O157 TW14359 genome (18).^b Considered to be significantly different (*P* < 0.0007).

Identification of putative virulence determinant genes and allelic variants. Following our designation of the most prevalent O157 strains from both Argentina and Australia as LI/II, we investigated if putative TW14359 virulence factor genes were also present (Table 5). The presence of the putative heme binding protein gene (ECSP_3286) carried by the TW14359 *stx*₂ (*argW*) prophage in 97% (36/37) of Argentinean O157 isolates was significantly different (*P* < 0.0001) from the presence in a single Australian O157 strain also carrying *stx*₂ (*argW*) prophage. *ospB* (ECSP_2687), carried by the TW14359 *stx*_{2c} (*sbcB*) prophage, was present in 43/46 Argentinean and 54/55 Australian O157 strains also carrying the *stx*_{2c} (*sbcB*) prophage. Three Argentinean isolates shown to carry *stx*₂ but not *stx*_{2c} tested positive for ECSP_2687. These isolates also contained an occupied *sbcB* locus, suggesting that they may carry *stx*_{2c}-negative *sbcB* prophage. Of the additional potential virulence determinants associated with the TW14359 genome, ECSP_1773 was present in 16/60 Argentinean strains and 14/60 Australian strains. ECSP_2870 and ECSP_2872 were present together in a higher proportion of Argentinean strains (38/60) than Australian strains (24/60); however, this was not statistically significant (*P* > 0.007). In the Australian strains, ECSP_2870 and ECSP_2872 were present together in significantly more human isolates (17/30) than animal isolates (7/30) (*P* < 0.05). Ankyrin repeat elements (ECSP_0242) were present in 56/60 Argentinean and the majority of Australian strains (55/60). Similarly, the nitric oxide reductase gene *norV* (ECSP_3620) was present in 57/60 Argentinean and the majority of Australian strains (58/60). All isolates carrying *norV* were non-LI and also belonged to either clade 4, 6, 7, or 8. All Argentinean (*n* = 3) and Australian (*n* = 2) O157 isolates that carried a Δ *norV* allele (204-bp deletion homologous to EDL933 and Sakai strains) were shown to belong to LI. Therefore, significant associations of ankyrin repeat presence with LI/II (*P* < 0.05) and *norV* presence with LI/II (*P* < 0.05) were evident. Additional analysis of the translocated intimin receptor gene *tir* alleles, previously used to discriminate clinical O157 strains, revealed that with the exception of four Australian isolates possessing *tir*255A, all other Argentinean (60/60) and Australian O157 isolates (56/60) possessed the *tir*255T allele.

DISCUSSION

The prevalences of particular *stx* genotypes in *E. coli* O157 isolates from different geographic origins have previously been reported (8, 22, 25). Fegan and Desmarchelier (8) tested 102 Australian *E. coli* O157 isolates from human and animal sources for the pres-

ence of *stx*₁, *stx*₂, and *stx*_{2c}. Their findings demonstrated the following *stx* genotypes: *stx*₁ *stx*_{2c} (74%), *stx*_{2c} (16%), *stx*₁ *stx*₂ (5%), *stx*₂ *stx*_{2c} (3%), and *stx*₁ (3%). Studies from Argentina have also demonstrated predominance of the particular genotype *stx*₂ *stx*_{2c} (22, 25). Isolates in the current study represented multiple genotypes in proportions similar to the diversity previously demonstrated in Argentina and Australia. Consistent with this, we observed a significant difference between the dominant *stx*₂ *stx*_{2c} (Argentina) and *stx*₁ *stx*_{2c} (Australia) genotypes in this study.

The high prevalence of dominant but contrasting *stx* genotypes in Argentina and Australia provoked our investigation of Shiga-toxin bacteriophage insertion (SBI) sites in diverse sets of epidemiologically representative O157 isolates from each country. Through this we have demonstrated that *stx*₁-positive Australian isolates dominantly carry novel *stx*₁ prophage in the *argW* locus, which had previously been described only as a locus for *stx*₂ prophage insertion (18, 29). Additionally, we have demonstrated that, in common with the U.S. spinach-associated outbreak strain TW14359 (18), Argentinean *stx*₂ isolates most commonly carry *stx*₂ prophage in *argW*. These data suggest that *stx*₁-positive Australian isolates can be distinguished from Argentinean isolates on the basis of unique SBI profiles. Importantly, the novel combination of *stx*₁ linkage with *argW* prophage insertion was verified by transduction of representative *stx*₁ (*argW*) prophage to form *E. coli* K-12 lysogens. While both *stx*₁ (*argW*) and *stx*₂ (*argW*) prophages and their *argW* integration site were identified with the same primer pairs (specific to the 5' and 3' prophage/chromosome junctions, implying phage genome sequence similarity), the absence of the gene for putative heme binding protein (ECSP_3286) in Australian *stx*₁ (*argW*) prophage genomes (K. S. Gobius, unpublished data), in addition to the alternative *stx* alleles, suggests further prophage sequence divergence.

In the context of our discovery of the novel *stx*₁ (*argW*) prophage in Australian O157, we also prioritized attempts to characterize the *stx*₁ prophage in 14 non-LI Argentinean O157 strains. Since none of the loci, *yehV*, *wrbA*, *sbcB*, *argW*, *yecE*, or *prfC*, which have been previously noted as SBI sites in enterohemorrhagic *E. coli* (29), appeared to be occupied with *stx*₁ prophage, we attempted prophage induction, followed by lysogen formation in *E. coli* K-12 to identify the integration site(s). Despite numerous attempts at lysogeny, this approach to SBI characterization was also unsuccessful. As each of the 14 strains showed evidence consistent with prophage insertion in the *yehV* locus, it is tempting to speculate that the *stx*₁ regulon may be carried by a prophage at this site. However, since all other Argentinean LI/II and lineage untypeable strains also appear to possess non-*stx* prophages inserted at *yehV*, it is unlikely that *stx*₁ prophage inserts at this locus. As a consequence of this, the *stx*₁ prophage integration site for Argentinean isolates carrying *stx*₁ phage remains undetermined.

Consistent with previous studies (8, 25), we also observed a significant difference in the motility of O157 from Argentina (predominantly motile strains) and Australia (predominantly non-motile strains), further supporting potential differentiation of the O157 populations in each country.

LSPA-6 genotyping data revealed that the predominant O157 isolates of both Argentinean and Australian origins share a similar genetic backbone and are designated LI/II genotype 211111. Overall, the current data contrast with previous studies that have determined lineage heterogeneity of O157 strains based on host and/or pathogenicity. In North America, LI and LI/II strains are

dominant in humans infected with O157, and LII strains dominate in the cattle reservoir (38, 43, 44). In addition, Yokoyama et al. (42) recently established that in Chiba Prefecture, Japan, LI strains (52.5%), LI/II strains (31.5%), and LII strains (16%) are associated with human patients and asymptomatic carriers. Franz et al. (9) have also demonstrated in the Netherlands that LII isolates are most dominant in cattle, while LI/II strains, followed by LI strains, predominate among human isolates. Therefore, it is a notable contrast that in both Argentina and Australia, the single LSPA-6 phylogenetic lineage LI/II shows dominance in both cattle reservoirs and clinical disease manifestation. While we have shown that O157 strains with LSPA-6 LI and LII genotypes are also present in cattle and clinical isolates from Argentina and Australia, it appears that these alternative strains comprise a minor proportion of the O157 populations in both countries.

Following LSPA-6 genotyping, we examined the virulence clade types (24, 34) of Argentinean and Australian O157 isolates. Clade typing revealed additional phylogenetic insights, with clade 4, 6, 7, and 8 isolates observed to contribute to the composition of the LI/II genotype. Clade 8 isolates were first described by Manning et al. (24) in the United States and have subsequently been characterized in other countries, including Japan (41), Sweden (7), and Norway (13). The presence of clade 8 O157 strains in Argentina and Australia indicates that clade 8 strains are geographically widespread across several continents. Clade 6 and 7 isolates have been previously noted among U.S. O157 isolates which were designated LI/II (23); however, to the best of our knowledge, our study provides the first confirmation of virulence clade 4 association with LI/II. Furthermore, alternative country-specific and host-specific clade bias was observed between the two countries. In Argentina, clade 8 isolates dominated in both cattle and humans but were most prevalent in human cases. A similar pattern of clade dominance was observed for Australian isolates, where clade 7 dominated in both cattle and humans but was most prevalent in human cases.

Due to the severity of the U.S. spinach-associated O157 outbreak in 2006, a representative LI/II clade 8 outbreak strain, TW14359, has been characterized by SNP and genome analysis (18, 24). Seven putative virulence factors, not present in previously characterized LI and LII strains, were identified and considered with respect to their association with the alternative LSPA-6 lineages. Only one (ECSP_3286) of the seven putative virulence factors tested was shown to be more frequent in Argentinean isolates. The increased frequency of ECSP_3286, carried by the TW14359 *stx*₂ (*argW*) prophage, in Argentinean strains can be attributed to the different rate of *stx*₂ (*argW*) carriage in Argentinean and Australian isolates. On the basis of observed *stx*₁ prophage presence and Δ *norV* correlation, Kulasekara et al. (18) suggested that the presence of *stx*₁ prophage is selective for the Δ *norV* allele. In contrast, our data from Australian strains suggest that the Δ *norV* allele is not predisposed by the presence of *stx*₁. Alternatively, our data indicate that since Australian O157 isolates carrying *stx*₁ generally also carry an undelimited *norV* allele, rather than *stx*₁ selecting for the Δ *norV* allele, it is likely the prophage type (i.e., *stx*₁ [*yehV*] prophage) is associated with genomes possessing the Δ *norV* allele. Extending this reasoning, it is also possible that complete *norV* genes are a feature of LI/II genomes, whereas Δ *norV* alleles may be a feature of at least LI genomes. Previously, it has also been suggested that the *tir255T*→A polymorphism may act as a marker for virulence in *E. coli* O157 (4); however, a more specific

association of *tir255T* with LI/II strains was recently observed by Laing et al. (19). With the exception of four Australian isolates, all other O157 isolates (93%) examined in this study carried *tir255T*. Our data confirm the association of *tir255T* with LI/II but demonstrate its association with multiple clades (4, 6, 7, and 8) within this lineage, suggesting, in contrast to previous studies (4, 9), that this SNP may not be a specific predictor for strains likely to cause human disease.

We have shown that *stx_{2c}* prophage is common in LI/II O157 isolates (including Argentinean clade 4 and 8 and Australian clade 6 and 7 isolates). The presence of *stx_{2c}* prophage in such isolates is consistent with the nonrandom concentration of *stx_{2c}* in clades 4, 6, 7, and 8 in U.S. clinical O157 isolates observed by Manning et al. (24); however, we have noted *q* gene region heterogeneity in the Australian *stx_{2c}* prophage. Allelic variation in the *q* gene region upstream of *stx₂* and *stx_{2c}* was first reported by LeJeune et al. (20), who demonstrated that the *q₂₁* allele is characteristic for the *stx_{2c}* prophage. For Australian O157 strains in this study, we have described the presence of the *stx_{2c}* prophage carrying heterogenic *q₉₃₃* or *q₂₁* alleles immediately 5' of the *stx_{2c}* genes. The variable *q₉₃₃*- and *q₂₁*-related alleles were associated with *stx_{2c}* genes in both LI/II *stx₁* *stx_{2c}* or LI/II *stx_{2c}* Australian O157 strains. To date, all previously described O157 *stx_{2c}* genes have possessed *q₂₁* alleles encoding an apparent variant Q antiterminator protein (17, 20, 26, 37, 43); however, to our knowledge, the functionality of the Q₂₁ protein has not been demonstrated. Thus, it could be anticipated that the variable *q₉₃₃*- and *q₂₁*-related alleles might regulate different levels of Stx_{2c}, though further work is required to demonstrate such a relationship.

The presence of *E. coli* O157 isolates with related LI/II phylogeny, and which show evidence as the most prevalent strains in both Argentina and Australia, raises the possibility that these strains possess an ancient relationship. Leopold et al. (21) recently used high-throughput pyrosequencing to determine the nucleotide sequence of several O157 strains and developed a set of SNPs to examine probable ancestral phylogenetic linkages of O157 strains. Their data indicate that strain TW14359 is a representative of EHEC 1 clade, subgroup 3, cluster 1 strains (alternatively defined as LI/II clade 8 [19, 24]) which evolved at an earlier time than the more recent EHEC 1 clade, subgroup 3, cluster 3 strains EDL933 (31) and Sakai (14). Leopold et al. also suggest the likelihood that radiating evolution, with subsequent genetic bottlenecking, followed the emergence of the cluster 1/LI/II founder organism, to result in the extinction of particular radiating branches and the current limited pool of cluster 1 (LSPA-6 LI/II) strains. Since the current study supports the cluster 1 (LSPA-6 LI/II) designation of the dominant O157 strains from both Argentina and Australia, further phylogenomic investigation may determine the precise radial branch location of these strains.

In conclusion, we have demonstrated that diverse sets of *E. coli* O157 isolated in Argentina and Australia are differentiated by separate dominant phylogenetic clades. In Argentina, LI/II clade 8 strains with *stx₂* prophage integrated in the *argW* chromosomal insertion site were most prevalent, whereas in Australia, LI/II clade 7 strains with *stx₁* prophage integrated in the *argW* chromosomal insertion site were most prevalent. This O157 genotype differentiation was present in isolates causing human illness, as well as isolates from the animal reservoirs of each respective country. It is enticing to speculate that the correlation of separate country-specific genotypes in clinical and animal O157 isolates may

provide the basis for observed differences in both the prevalence and severity of human disease caused by O157 in Australia (low) and Argentina (high). These data now provide evidence for the geographical segregation of *E. coli* O157 strains in which distinctive clade and Shiga toxin prophage combinations may provide genetic markers for *E. coli* O157 strains with various pathogenic potential. Examination of more extensive collections from each country, coupled with animal model comparisons of the virulence of different Argentinean and Australian O157 clades, is now recommended to provide further confirmation of these data.

ACKNOWLEDGMENTS

We thank John Bates and Helen Smith (Reference Microbiology and Molecular Epidemiology Laboratories, Queensland Health, Australia) for the kind provision of human O157 isolates. Fruitful discussion with Narelle Fegan, expert statistical advice from Richard Wilson, and helpful comments from the reviewers are gratefully acknowledged.

This study was supported by strategic research funds from CSIRO and Department of Primary Industries Victoria.

REFERENCES

- Allison HE, et al. 2003. Immunity profiles of wild-type and recombinant Shiga-like toxin-encoding bacteriophages and characterization of novel double lysogens. *Infect. Immun.* 71:3409–3418.
- Anonymous. 1993. Update: multistate outbreak of *Escherichia coli* O157:H7 infections from hamburgers—western United States, 1992–1993. *MMWR Morb. Mortal. Wkly. Rep.* 42:258–263.
- Besser TE, et al. 2007. Greater diversity of Shiga toxin-encoding bacteriophage insertion sites among *Escherichia coli* O157:H7 isolates from cattle than in those from humans. *Appl. Environ. Microbiol.* 73:671–679.
- Bono JL, et al. 2007. Association of *Escherichia coli* O157:H7 *tir* polymorphisms with human infection. *BMC Infect. Dis.* 7:98.
- Caprioli A, Morabito S, Brugere H, Oswald E. 2005. Enterohaemorrhagic *Escherichia coli*: emerging issues on virulence and modes of transmission. *Vet. Res.* 36:289–311.
- Erickson MC, Doyle MP. 2007. Food as a vehicle for transmission of Shiga toxin-producing *Escherichia coli*. *J. Food Prot.* 70:2426–2449.
- Eriksson E, Soderlund R, Boqvist S, Aspan A. 2011. Genotypic characterization to identify markers associated with putative hypervirulence in Swedish *Escherichia coli* O157:H7 cattle strains. *J. Appl. Microbiol.* 110:323–332.
- Fegan N, Desmarchelier P. 2002. Comparison between human and animal isolates of Shiga toxin-producing *Escherichia coli* O157 from Australia. *Epidemiol. Infect.* 128:357–362.
- Franz E, et al. 2012. Genetic features differentiating bovine, food, and human isolates of Shiga toxin-producing *Escherichia coli* O157 in The Netherlands. *J. Clin. Microbiol.* 50:772–780.
- Friedrich AW, et al. 2002. *Escherichia coli* harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. *J. Infect. Dis.* 185:74–84.
- Gannon VP, et al. 1997. Use of the flagellar H7 gene as a target in multiplex PCR assays and improved specificity in identification of enterohaemorrhagic *Escherichia coli* strains. *J. Clin. Microbiol.* 35:656–662.
- Hancock D, Besser T, Lejeune J, Davis M, Rice D. 2001. The control of VTEC in the animal reservoir. *Int. J. Food Microbiol.* 66:71–78.
- Haugum K, Brandal LT, Lobersli I, Kapperud G, Lindstedt BA. 2011. Detection of virulent *Escherichia coli* O157 strains using multiplex PCR and single base sequencing for SNP characterization. *J. Appl. Microbiol.* 110:1592–1600.
- Hayashi T, et al. 2001. Complete genome sequence of enterohaemorrhagic *Escherichia coli* O157:H7 and genomic comparison with a laboratory strain K-12. *DNA Res.* 8:11–22.
- Karn J, Brenner S, Barnett L, Cesareni G. 1980. Novel bacteriophage lambda cloning vector. *Proc. Natl. Acad. Sci. U. S. A.* 77:5172–5176.
- Kim J, et al. 2001. Ancestral divergence, genome diversification, and phylogeographic variation in subpopulations of sorbitol-negative, beta-glucuronidase-negative enterohaemorrhagic *Escherichia coli* O157. *J. Bacteriol.* 183:6885–6897.
- Koitaishi T, et al. 2006. Genetic characterization of *Escherichia coli*

- O157: H7/- strains carrying the *stx2* gene but not producing Shiga toxin 2. *Microbiol. Immunol.* 50:135–148.
18. Kulasekara BR, et al. 2009. Analysis of the genome of the *Escherichia coli* O157:H7 2006 spinach-associated outbreak isolate indicates candidate genes that may enhance virulence. *Infect. Immun.* 77:3713–3721.
 19. Laing CR, et al. 2009. In silico genomic analyses reveal three distinct lineages of *Escherichia coli* O157:H7, one of which is associated with hypervirulence. *BMC Genomics* 10:287.
 20. LeJeune JT, Abedon ST, Takemura K, Christie NP, Sreevatsan S. 2004. Human *Escherichia coli* O157:H7 genetic marker in isolates of bovine origin. *Emerg. Infect. Dis.* 10:1482–1485.
 21. Leopold SR, et al. 2009. A precise reconstruction of the emergence and constrained radiations of *Escherichia coli* O157 portrayed by backbone concatenomic analysis. *Proc. Natl. Acad. Sci. U. S. A.* 106:8713–8718.
 22. Leotta GA, et al. 2008. Characterisation of Shiga toxin-producing *Escherichia coli* O157 strains isolated from humans in Argentina, Australia and New Zealand. *BMC Microbiol.* 8:46.
 23. Liu K, Knabel SJ, Dudley EG. 2009. *rhs* genes are potential markers for multilocus sequence typing of *Escherichia coli* O157:H7 strains. *Appl. Environ. Microbiol.* 75:5853–5862.
 24. Manning SD, et al. 2008. Variation in virulence among clades of *Escherichia coli* O157:H7 associated with disease outbreaks. *Proc. Natl. Acad. Sci. U. S. A.* 105:4868–4873.
 25. Masana MO, et al. 2010. Prevalence, characterization, and genotypic analysis of *Escherichia coli* O157:H7/NM from selected beef exporting abattoirs of Argentina. *J. Food Prot.* 73:649–656.
 26. Matsumoto M, et al. 2008. Identification and epidemiological description of enterohemorrhagic *Escherichia coli* O157 strains producing small amounts of Shiga toxin 2 in Aichi Prefecture, Japan. *Jpn. J. Infect. Dis.* 61:442–445.
 27. McPherson M, et al. 2009. Serogroup-specific risk factors for Shiga toxin-producing *Escherichia coli* infection in Australia. *Clin. Infect. Dis.* 49:249–256.
 28. Nishikawa Y, et al. 2000. Relationship of genetic type of Shiga toxin to manifestation of bloody diarrhea due to enterohemorrhagic *Escherichia coli* serogroup O157 isolates in Osaka City, Japan. *J. Clin. Microbiol.* 38:2440–2442.
 29. Ogura Y, et al. 2009. Comparative genomics reveal the mechanism of the parallel evolution of O157 and non-O157 enterohemorrhagic *Escherichia coli*. *Proc. Natl. Acad. Sci. U. S. A.* 106:17939–17944.
 30. Paton AW, Paton JC. 1998. Detection and characterization of Shiga toxinogenic *Escherichia coli* by using multiplex PCR assays for *stx1*, *stx2*, *eaeA*, enterohemorrhagic *E. coli hlyA*, *rfbO111*, and *rfbO157*. *J. Clin. Microbiol.* 36:598–602.
 31. Perna NT, et al. 2001. Genome sequence of enterohaemorrhagic *Escherichia coli* O157:H7. *Nature* 409:529–533.
 32. Persson S, Olsen KE, Ethelberg S, Scheutz F. 2007. Subtyping method for *Escherichia coli* Shiga toxin (verocytotoxin) 2 variants and correlations to clinical manifestations. *J. Clin. Microbiol.* 45:2020–2024.
 33. Rangel JM, Sparling PH, Crowe C, Griffin PM, Swerdlow DL. 2005. Epidemiology of *Escherichia coli* O157:H7 outbreaks, United States, 1982–2002. *Emerg. Infect. Dis.* 11:603–609.
 34. Riordan JT, Viswanath SB, Manning SD, Whittam TS. 2008. Genetic differentiation of *Escherichia coli* O157:H7 clades associated with human disease by real-time PCR. *J. Clin. Microbiol.* 46:2070–2073.
 35. Rivas M, Miliwebsky ES, Chinen I, Deza N, Leotta GA. 2006. Epidemiology of the hemolytic uremic syndrome in Argentina. Diagnosis of the etiological agent, reservoirs and routes of transmission. *Medicina (Buenos Aires)* 66:27–32.
 36. Shaikh N, Tarr PI. 2003. *Escherichia coli* O157:H7 Shiga toxin-encoding bacteriophages: integrations, excisions, truncations, and evolutionary implications. *J. Bacteriol.* 185:3596–3605.
 37. Strauch E, et al. 2008. Bacteriophage 2851 is a prototype phage for dissemination of the Shiga toxin variant gene 2c in *Escherichia coli* O157:H7. *Infect. Immun.* 76:5466–5477.
 38. Whitworth J, et al. 2010. Diverse genetic markers concordantly identify bovine origin *Escherichia coli* O157 genotypes underrepresented in human disease. *Appl. Environ. Microbiol.* 76:361–365.
 39. Whitworth JH, et al. 2008. International comparison of clinical, bovine, and environmental *Escherichia coli* O157 isolates on the basis of Shiga toxin-encoding bacteriophage insertion site genotypes. *Appl. Environ. Microbiol.* 74:7447–7450.
 40. Yang Z, et al. 2004. Identification of common subpopulations of non-sorbitol-fermenting, beta-glucuronidase-negative *Escherichia coli* O157:H7 from bovine production environments and human clinical samples. *Appl. Environ. Microbiol.* 70:6846–6854.
 41. Yokoyama E, et al. 2011. Emergence of enterohemorrhagic *Escherichia coli* serovar O157 strains in clade 8 with highly similar pulsed-field gel electrophoresis patterns. *J. Food Prot.* 74:1324–1327.
 42. Yokoyama E, et al. 2011. Biased distribution of IS629 among strains in different lineages of enterohemorrhagic *Escherichia coli* serovar O157. *Infect. Genet. Evol.* 11:78–82.
 43. Zhang Y, et al. 2010. Lineage and host source are both correlated with levels of Shiga toxin 2 production by *Escherichia coli* O157:H7 strains. *Appl. Environ. Microbiol.* 76:474–482.
 44. Ziebell K, et al. 2008. Genotypic characterization and prevalence of virulence factors among Canadian *Escherichia coli* O157:H7 strains. *Appl. Environ. Microbiol.* 74:4314–4323.